| http://www.w3.org/ns/prov#value | - Closer to realizationSince Alnylam's potential hepatitis B treatment is years away, investors may want to concentrate on compounds closer to market, including Gilead's tenofovir alafenamide, a drug being studied as a treatment for both HIV and hepatitis B.
|
